Alexion Pharmaceuticals

Alexion is a global biopharmaceutical company focused on developing and delivering life-transforming therapies for patients with devastating and rare diseases. It is engaged in the discovery, development and commercialization of biologic therapeutic products aimed at treating patients with severe and life-threatening disease states, including hematologic, kidney and neurologic diseases, transplant rejection, cancer and autoimmune disorders. Its marketed product Soliris (eculizumab) is a therapy approved for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH).
Company Growth (employees)
Type
Public
HQ
New Haven, US
Founded
1992
Size (employees)
3,121 (est)
Alexion Pharmaceuticals was founded in 1992 and is headquartered in New Haven, US

Alexion Pharmaceuticals Office Locations

Alexion Pharmaceuticals has offices in New Haven, Zürich, Barcelona, London and in 26 other locations
New Haven, US (HQ)
100 College St
Zürich, CH
30 Giesshübelstrasse
Show all (31)

Alexion Pharmaceuticals Data and Metrics

Alexion Pharmaceuticals Financial Metrics

Alexion Pharmaceuticals's revenue was reported to be $870 m in Q1, 2017
USD

Revenue (Q1, 2017)

870 m

Gross profit (Q1, 2017)

801 m

Gross profit margin (Q1, 2017), %

92%

Net income (Q1, 2017)

170 m

EBIT (Q1, 2017)

212 m

Market capitalization (15-Aug-2017)

30.4 b

Cash (31-Mar-2017)

713 m
Alexion Pharmaceuticals's current market capitalization is $30.4 b.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

1.6 b2.2 b2.6 b3.1 b

Revenue growth, %

44%17%18%

Cost of goods sold

233.1 m258 m

Gross profit

1.4 b2.1 b2.4 b2.8 b

Gross profit Margin, %

89%92%91%92%

R&D expense

757 m

General and administrative expense

954 m

Operating expense total

845.8 m1.2 b1.8 b2.2 b

EBIT

528 m868.7 m536.7 m667 m

EBIT margin, %

34%39%21%22%

Interest expense

47.7 m97 m

Pre tax profit

498.1 m576 m

Income tax expense

353.8 m177 m

Net Income

252.9 m656.9 m144.4 m399 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

636.2 m666.6 m701 m753.1 m799.1 m870 m

Cost of goods sold

39.6 m51.9 m69.4 m52 m54.1 m59 m60.6 m71.1 m69 m

Gross profit

584.2 m612.6 m642.1 m692.5 m728 m801 m

Gross profit Margin, %

92%92%92%92%91%92%

R&D expense

92.6 m100.7 m221.1 m131.7 m165.7 m176.3 m179.3 m195.7 m219 m

General and administrative expense

159.5 m157.7 m187.1 m221.4 m212.5 m232.6 m231.8 m230.1 m262 m

Operating expense total

252 m258.3 m408.2 m353.1 m378.2 m408.9 m411.1 m425.8 m481 m

EBIT

218.8 m236.7 m103.7 m181.1 m154.6 m165.8 m194.7 m179.3 m212 m

EBIT margin, %

28%23%24%26%22%24%

Interest expense

(715 k)(655 k)(651 k)(4 m)(20 m)(23.9 m)(23.8 m)(24.8 m)(24 m)

Pre tax profit

218.6 m236.2 m106.9 m177.3 m139.4 m143.6 m170 m158.1 m194 m

Income tax expense

52.2 m58.5 m15.6 m7.1 m323.1 m51.4 m55 m63.8 m24 m

Net Income

166.5 m177.7 m91.3 m170.2 m(183.8 m)92.2 m114.9 m94.3 m170 m
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

529.9 m944 m1 b966 m

Accounts Receivable

650 m

Inventories

102.6 m176.4 m289.9 m375 m

Current Assets

2.2 b2.8 b2.4 b2.6 b

PP&E

201.1 m392.2 m697 m1 b

Goodwill

254.1 m254.1 m5 b5 b

Total Assets

3.3 b4.2 b13.1 b13.3 b

Accounts Payable

21.6 m44 m57.4 m64 m

Total Debt

167 m

Current Liabilities

582.4 m606.7 m718.3 m823 m

Total Liabilities

4.6 b

Additional Paid-in Capital

2.1 b2.6 b7.7 b8 b

Retained Earnings

379.1 m1 b1.2 b1.8 b

Total Equity

2.4 b3.3 b8.3 b8.7 b

Debt to Equity Ratio

0 x

Debt to Assets Ratio

0 x

Financial Leverage

1.4 x1.3 x1.6 x1.5 x
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

612 m752.2 m916.8 m1.3 b1.2 b710.2 m597.6 m762 m713 m

Accounts Receivable

440.7 m436.5 m479.9 m535.8 m512.3 m586.2 m609.3 m676.8 m660 m

Inventories

144.9 m140 m174.5 m234.3 m236.5 m294 m329.8 m363.1 m396 m

Current Assets

2.3 b2.6 b2.9 b2.5 b2.5 b2.1 b2.4 b2.6 b2.7 b

PP&E

273.3 m328.5 m440.5 m555.4 m618.7 m749.3 m825.3 m931.1 m1.1 b

Goodwill

254.1 m254.1 m254.1 m5 b5 b5 b5 b5 b5 b

Total Assets

3.6 b3.9 b4.4 b13.2 b13.2 b12.8 b13 b13.3 b13.4 b

Accounts Payable

36.1 m23.2 m52.9 m47 m47 m42.9 m29 m44.8 m61 m

Current Liabilities

417.7 m502.5 m580.4 m769.2 m766.9 m603.6 m658.5 m1 b837 m

Additional Paid-in Capital

2.5 b2.6 b2.7 b7.7 b7.6 b7.8 b7.9 b7.9 b8.1 b

Retained Earnings

704.9 m882.7 m1.1 b1.3 b1.1 b1.3 b1.4 b1.7 b2 b

Total Equity

2.9 b3.1 b3.5 b8.6 b8.3 b8.1 b8.2 b8.5 b8.9 b

Financial Leverage

1.2 x1.2 x1.3 x1.5 x1.6 x1.6 x1.6 x1.6 x1.5 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

252.9 m656.9 m144.4 m399 m

Depreciation and Amortization

28.7 m46.9 m166.6 m396 m

Accounts Receivable

(120 m)(28 m)(120 m)(122 m)

Inventories

126 k(67 m)(88 m)(84 m)

Cash From Operating Activities

497.3 m640.1 m675.2 m1.1 b

Purchases of PP&E

(29.3 m)(136.7 m)(286.3 m)(333 m)

Cash From Investing Activities

(1 b)(222.9 m)(3.6 b)(287 m)

Cash From Financing Activities

71.6 m7.1 m3 b(836 m)

Interest Paid

2.8 m1.9 m41.4 m80 m

Income Taxes Paid

76.2 m91.2 m123.2 m38 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

166.5 m177.7 m91.3 m170.2 m(183.8 m)92.2 m114.9 m94.3 m170 m

Inventories

144.9 m140 m174.5 m234.3 m236.5 m294 m329.8 m363.1 m396 m

Accounts Payable

36.1 m23.2 m52.9 m47 m47 m42.9 m29 m44.8 m61 m
USDY, 2017

Revenue/Employee

278.8 k

Financial Leverage

1.5 x

Alexion Pharmaceuticals Market Value History

Alexion Pharmaceuticals Median Salaries

Source: 33 public H-1B filings from Alexion Pharmaceuticals

Traffic Overview of Alexion Pharmaceuticals

Alexion Pharmaceuticals Online and Social Media Presence

Alexion Pharmaceuticals News and Updates

Hacking DNA: All The Corporates Betting On Synthetic Biology Startups In One Timeline

In a milestone year, global funding to private synthetic biology startups surpassed $1B in 2016. While biological engineering is not a new science, the surging reliability of genetic editing techniques and their increasingly creative applications have led to synthetic biology startups … Continued

The CEO and CFO of rare disease drugmaker Alexion just left the company (ALXN)

Two top executives at Alexion Pharmaceuticals have left the company. Alexion, a company that makes treatments for rare diseases, said on Monday that Chief Executive David Hallal had resigned, effective immediately, and named board member David Brennan as interim CEO. The com…

MORGAN STANLEY: Here are 30 stocks that'll thrive even if the economy gets worse (ALXN, ALGN, GOOGL, AMZN, AMT, ATHN, TEAM, BUFF, CELG, CONE, EW, EQIX, FB, FIVE, IPHI, LULU, MNST, NFLX, PANW, PFPT, RHT, CRM, SBAC, NOW, SPLK, SBUX, TPIC, VEEV, V, WDAY, SPY, SPX, DJI, IXIC, IWIM)

Morgan Stanley has updated its annual list of secular growth stocks.  In a note published on Thursday, the firm highlighted 30 stocks that its analysts believe would thrive even if the global economy grows slower than they forecast.  To compile the list, Morgan Stanley first…

Stocks move lower in quiet trading; oil prices fall sharply

Stocks closed nearly flat in quiet trading Monday after drifting most of the day between gains and losses. Energy companies fell along with the price of oil while biotechnology and drug companies rose after Pfizer announced it was buying a cancer drug maker. Trading remained subdued, as it has..…

These 10 Stocks Have Beaten Google’s 1,780% Gain Since Its IPO

Another 17 companies lost more their half their value over the same period.

10 things you need to know before the opening bell (spy, spx, qqq, dia, wba, bx, vtr, tsla, twtr, fb)

Here is what you need to know. The British pound made a fresh 31-year low. Another day, another fresh 31-year low for the British pound. Sterling sank to 1.2798 in overnight action as traders continued to punish the currency amid the fallout from the Brexit vote. According t…

Alexion Pharmaceuticals Company Life and Culture

You may also be interested in